Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase AuthorizationBusiness Wire • 01/28/25
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal CancerZacks Investment Research • 01/27/25
FDA Grants Priority Review to Merck's Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)Business Wire • 01/27/25
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024The Motley Fool • 01/25/25
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trialReuters • 01/24/25
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal AdenocarcinomaBusiness Wire • 01/24/25
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?The Motley Fool • 01/21/25
Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4Business Wire • 01/16/25
3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold ForeverThe Motley Fool • 01/16/25
Merck & Co. Inc. (MRK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/14/25
3 Ideal Buys From 51 'Safer' Dividends In 100 January Barron's Sustainable DogsSeeking Alpha • 01/11/25